This Coronavirus-Test Developer Could Surge 60%+ According To One Analyst

One analyst says this small diagnostics firm has demonstrated its ability and is now a Buy.

As confirmed cases of COVID-19 climb towards 76,000 and total deaths from the virus outbreak surpass 2,130, there’s one small diagnostics firm that investors may want to keep an eye on.

Nano cap Co-Diagnostics (NASDAQ: CODX) started garnering some attention last month when the stock skyrocketed 148% after the company announced that it had completed the principle design work for a PCR screening test for the coronavirus just weeks after the outbreak began in China.

Since that announcement, Co-Diagnostics shares are up around 50%, and there’s one analyst that says the stock could surge far higher still.

Maxim Group analyst Jason McCarthy issued a Buy rating on the stock in a note this week and raised his price target from $2 to $5 – 64% higher than the price as of this writing. 

“We view this as de-risking of the platform, as a real-world example of how quickly [Co-Diagnostics] can develop a test in response to a novel viral outbreak,” McCarthy wrote in the note. “We also see the increased media attention as a positive which could help drive adoption, lowering commercial risk.”

According to McCarthy, the surge in interest as a result of the coronavirus has allowed Co-Diagnostics to raise $15 million in the public markets over the last few weeks, giving the company enough cash to operate into 2021.

What’s more, so far this year, Co-Diagnostics shares are up a jaw-dropping 236%, and up nearly 151% over the last 12 months. 

“The company has demonstrated the ability to rapidly develop tests for emerging diseases like Zika and Ebola, and now the coronavirus, thereby highlighting the versatility of its platform, as well as demonstrating that the company will be able to develop tests for future emerging outbreaks,” McCarthy wrote.

While McCarthy noted that the test for COVID-19 may not generate much in the way of revenue for Co-Diagnostics, it is a demonstration of the company’s capabilities.

The company announced its first sales of the test, for research purposes only, on February 10, with CEO Dwight Egan commenting that “The rapid development and time to commercialization was possible thanks to the innovation of our proprietary and patented platform, our dedicated employees, and the support of our suppliers. We are pleased to be able to offer a product to this market that excels in being both sensitive and specific, the two benchmarks for accuracy in molecular diagnostics.”

Co-Diagnostics also announced Thursday that it has submitted the technical file for its COVID-19 test for registration with the European Community and expects it will be available later this month as an in vitro diagnostic tool. 

“We are pleased to announce this milestone, which comes after weeks of hard work by our team at Co-Diagnostics to develop a high-performance diagnostic to help prevent the spread of the new strain of coronavirus,” Egan said in a statement. “Our patented CoPrimer™ molecules have unique properties that lead to a significant reduction in false positive test results over other polymerase chain reaction (PCR) technologies, but will also allow for enhanced multiplexing, or identifying multiple targets at once, as we iterate the test to include other strains of coronavirus and mutations of COVID-19.”

By the way, if you liked this article, you'll LOVE this Meaty free training I just published on the top 3 questions and challenges every investor faces AND how to overcome them. It's titled "10k into $2.4 Million in 18 months" and you can grab it for free here

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company’s software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

FREE TRAINING - TRADERSPRO PRESENTS: Retire In 18 Months With $2.4 Million?

Join Us Now